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Dominant mutations in the MORC2 gene have recently been shown to 
cause axonal Charcot-Marie-Tooth (CMT) disease, but the cellular function of 
MORC2 is poorly understood. Here, through a genome-wide CRISPR/Cas9-
mediated forward genetic screen, we identify MORC2 as an essential gene 
required for epigenetic silencing by the HUSH complex. HUSH recruits MORC2 
to target sites in heterochromatin. We exploit a new method – Differential Viral 
Accessibility (DIVA) – to show that loss of MORC2 results in chromatin 
decompaction at these target loci, which is concomitant with a loss of H3K9me3 
deposition and transcriptional derepression. The ATPase activity of MORC2 is 
critical for HUSH-mediated silencing, and the most common mutation affecting 
the ATPase domain found in CMT patients (R252W) hyper-activates HUSH-
mediated repression in neuronal cells. These data define a critical role for 
MORC2 in epigenetic silencing by the HUSH complex and provide a mechanistic 
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Chromatin has historically been considered as existing in one of two distinct 
states: euchromatin or heterochromatin. Euchromatin is generally considered to be 
gene-rich, transcriptionally-active and associated with an open and accessible 
conformation, whereas heterochromatin is comparatively gene-poor, highly 
condensed and refractory to the transcription machinery1. Heterochromatin has 
traditionally been considered as occurring in two distinct flavors: H3K27me3-marked 
heterochromatin, which is dynamic during development2, and H3K9me3-marked 
heterochromatin, which is typically found at repeat-rich regions3.  
A remarkable property of H3K9me3-marked heterochromatin is that it can 
‘spread’ along the arm of a chromosome, which can result in the epigenetic repression 
of an active gene when it is placed in the vicinity of a heterochromatic domain4. This 
phenomenon gives rise to chromosomal position-effects, a term which refers to the 
difference in expression when an identical gene is positioned at different sites in the 
genome5,6. We previously exploited the near-haploid KBM7 cell line7,8 to identify genes 
required for position-effect variegation in human cells9. By isolating a population of 
cells that displayed epigenetic repression of an integrated green fluorescent protein 
(GFP) reporter construct and screening for mutants in which this repression was 
alleviated, we identified four genes that were essential for transgene repression: the 
histone lysine methyltransferase SETDB110, plus the Human Silencing Hub (HUSH) 
complex subunits TASOR, MPP8 and Periphilin9. Through the chromodomain of 
MPP811, HUSH preferentially localizes to genomic loci rich in the repressive histone 
modification H3K9me3. HUSH-mediated recruitment of the methyltransferase 
SETDB1 to these sites results in the ‘writing’ of additional H3K9me3, thereby 
mediating the spreading of heterochromatin across incoming transgenes9. The HUSH 
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complex also plays a critical role in endogenous heterochromatin maintenance, as 
deletion of HUSH subunits results in decreased H3K9me3 at hundreds of genomic 
loci9 and early embryonic lethality in the mouse12,13.  
HUSH-mediated silencing is achieved through the reading and writing of 
H3K9me3. However, in order to understand how the deposition of this modification 
ultimately results in epigenetic repression, knowledge of the full complement of HUSH 
components is essential. Although our original haploid screen identified the core 
HUSH complex members and SETDB1, our recent examination of the efficacy of the 
haploid gene-trap approach suggested that such screens are unlikely to achieve 
saturation14. HUSH-mediated silencing may therefore require additional factors not 
identified by the original gene-trap screen, and, in support of this idea, we recently 
identified ATF7IP as an additional factor required for HUSH-mediated repression using 
a proteomic approach15.  
With the aim of identifying additional genes required for transgene silencing by 
the HUSH complex, we carried out a genome-wide forward genetic screen using 
CRISPR/Cas9 technology16,17. The CRISPR screen highlighted one additional gene 
as critical for HUSH-mediated repression: Microchidia CW-type zinc finger 
2 (MORC2). We show that HUSH recruits MORC2 to heterochromatic sites, where its 
ATPase activity is required to mediate transgene silencing. Loss of MORC2 results in 
chromatin decompaction at HUSH target loci, concomitant with a loss of H3K9me3 
and transcriptional derepression. Mutations in the ATPase domain of MORC2 have 
recently been implicated in Charcot-Marie-Tooth (CMT) disease, one of the most 
frequently inherited neurological disorders. We show that the most common of these 
mutations (R252W; p.Arg252Trp) results in hyper-activation of HUSH-mediated 
silencing in neuronal cells. Overall, this study identifies a critical role for MORC2 in 
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HUSH-mediated repression and provides further insight into the mechanisms 





















A genome-wide CRISPR screen identifies an essential role for MORC2 in HUSH-
mediated silencing. 
The rapid emergence of CRISPR/Cas9-mediated genome editing technologies 
has now allowed us to reevaluate the set of genes required for HUSH-mediated 
transgene silencing (Fig. 1a). The Cas9 nuclease was expressed in the same 
population of GFPdim KBM7 cells harboring epigenetically-repressed transgenes that 
we used previously9, and genome-wide CRISPR-mediated mutagenesis was 
performed using the GeCKO v2 sgRNA library18. Two rounds of fluorescence-
activated cell sorting (FACS) were used to enrich for GFPbright cells in which epigenetic 
repression of the GFP reporter transgene was relieved (Fig. 1b), and sgRNA 
abundance in the selected GFPbright cells versus the unselected library of mutagenized 
cells was quantified by Illumina sequencing (Fig. 1c and Supplementary Fig. 1a).  
Five genes are known to be critical for HUSH-mediated transgene repression: 
the three HUSH complex subunits TASOR, MPP8 and Periphilin9, plus the histone 
methyltransferase SETDB19 and its accessory factor ATF7IP15. Three of these 
positive controls, MPP8, SETDB1 and ATF7IP, were successfully identified by the 
CRISPR screen; TASOR and Periphilin were not significantly enriched, however, 
suggesting that the screen failed to reach saturation (Fig. 1c and Supplementary Fig. 
1a). Through individual CRISPR/Cas9-mediated gene disruption experiments, we 
assessed a potential role in transgene silencing for the other most significantly 
enriched genes (Supplementary Fig. 1b). This revealed an essential role for one 
additional gene, MORC2, a finding which we corroborated in an independent HeLa 
cell clone harboring a HUSH-repressed GFP reporter construct9 (Fig. 1d,e). With the 
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exception of SEL1L, which mediates the degradation of the GFP reporter at the protein 
level14, we were unable to validate any of the additional candidate genes 
(Supplementary Fig. 1b). Therefore, the genome-wide CRISPR screen identified a 
single novel gene, MORC2, as a bona fide factor required for HUSH-mediated 
transgene repression.    
 
The ATPase, CW and coiled-coil domains of MORC2 are essential for HUSH 
function. 
MORC2 is one of four MORC family proteins in humans (MORC1-4)19. Although 
little is known about their functional role in human cells, MORC family proteins have 
been implicated in epigenetic silencing in plants, worms, and mice20,21. MORC2 
encodes a protein containing a GHKL-type ATPase, comprised of the N-terminal 
ATPase domain plus an associated ribosomal protein S5-like domain, followed by two 
putative histone binding modules: a CW-type zinc finger and a chromo-like domain 
(Fig. 2a). To assess which of these domains were required for the function of MORC2 
in HUSH-mediated repression, we performed a series of genetic complementation 
experiments in a MORC2 knockout HeLa clone (Fig. 2b-d and Supplementary Table 
1). While exogenous expression of full-length MORC2 or a MORC2 mutant lacking the 
chromo-like domain resulted in re-repression of the GFP reporter, deletion of both 
ATPase domains, the S5-like domain alone or the CW-type zinc finger abolished 
MORC2 activity (Fig. 2e,f). Sequence analysis also predicted the presence of three 
coiled-coil domains (denoted CC1, CC2 and CC3) (Fig. 2a); deletion of any one of 
these also abrogated MORC2 function (Fig. 2e,f). Thus, the MORC2 ATPase domain, 
CW-type zinc finger and coiled-coil domains, but not the chromo-like domain, 
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appeared to be critical for HUSH-mediated epigenetic repression, with the caveat that 
although these mutant proteins are expressed in cells (Fig. 2f), we are unable to prove 
that they are correctly folded. 
 
MORC2 interacts with the HUSH complex. 
The genetic association between MORC2 and the HUSH complex suggested 
that MORC2 might physically interact with HUSH subunits. We were readily able to 
detect an interaction between a V5 epitope-tagged MORC2 immunoprecipitated from 
HeLa nuclei and the HUSH subunits TASOR and MPP8 (Fig. 3a). Repeating this 
assay with a series of V5-tagged N- and C-terminal truncation mutants of MORC2 
(Supplementary Table 1) suggested that the second coiled-coil domain (CC2) of 
MORC2 (residues 548-603) was likely to be essential for this interaction 
(Supplementary Fig. 2a-c). The interaction between MORC2 and HUSH subunits also 
occurred in SETDB1 knockout cells (Supplementary Fig. 2d) and deletion of MORC2 
did not prevent the interaction between SETDB1 and HUSH (Supplementary Fig. 2e), 
suggesting independent recruitment of these two potential effector proteins by the 
HUSH complex. However, like SETDB1, MORC2 did not appear to be a constitutive 
member of the HUSH complex, as, unlike loss of TASOR, MPP8 or Periphilin9, loss of 
MORC2 did not affect the protein levels of HUSH subunits (Supplementary Fig. 2f) nor 
their localization to chromatin (Supplementary Fig. 2g). 
 
The HUSH complex recruits MORC2 to heterochromatic loci. 
9 
  
To ascertain the physiological relevance of the association between MORC2 
and the HUSH complex, we performed chromatin immunoprecipitation followed by 
deep sequencing (ChIP-seq). Immunoprecipitation of a V5-tagged MORC2 construct 
expressed in MORC2 knockout cells revealed two modes of MORC2 binding to 
chromatin (Fig. 3b): a broad distribution across the bodies of genes located in 
heterochromatin marked by H3K9me3 (Fig. 3c,d and Supplementary Fig. 3a) and a 
series of discrete peaks at transcriptional start sites (TSSs) (Fig. 3e,f and 
Supplementary Fig. 3b). Comparing the occupancy of MORC2 with that of 
endogenous TASOR revealed significant overlap between the heterochromatic 
regions bound by MORC2 and those occupied by the HUSH complex (Fig. 3c,d). 
Indeed, MORC2 localization to these heterochromatic sites was dependent on the 
HUSH complex, as MORC2 occupancy was lost in cells lacking all three HUSH 
subunits (Fig. 3c,d). Thus, these datasets revealed HUSH-dependent recruitment of 
MORC2 to heterochromatic loci marked by H3K9me3. The functional relevance of 
MORC2 recruitment to TSSs remains unclear, but this was not dependent on the 
HUSH complex (Fig. 3e,f) and did not involve H3K4me3 recognition by the CW domain 
of MORC222 (Supplementary Fig. 4), as has been demonstrated for the CW domains 
of MORC3 and MORC423,24.  
In further support of an association between HUSH and MORC2, we also found 
that the HUSH complex regulated the expression of MORC2. Knockout of HUSH 
subunits or SETDB1 resulted in an increase in MORC2 expression as measured by 
quantitative reverse transcription PCR (qRT-PCR) (Supplementary Fig. 2h). In support 
of the idea that this represented a direct feedback loop, our ChIP-seq data 
demonstrated both TASOR occupancy and HUSH-dependent recruitment of MORC2 




MORC2 loss results in chromatin decompaction at HUSH loci. 
The catalytic activity of the MORC2 ATPase domain allows MORC2 to remodel 
nucleosomal templates in vitro25. Therefore, we hypothesized that ATP hydrolysis by 
MORC2 might be required to alter chromatin architecture at HUSH target sites in vivo. 
To directly test the functional requirement for MORC2 ATPase activity in HUSH-
mediated silencing, we carried out further genetic complementation assays in MORC2 
knockout HeLa cells (Fig. 4a). While exogenous expression of wild-type MORC2 
restored HUSH function and resulted in the re-repression of the GFP reporter 
construct, MORC2 variants harboring point mutations in the critical residues of the 
ATPase domain required for ATP binding (N39A) or hydrolysis (D68A)25 were non-
functional (Fig. 4a,b). 
Should the ATPase activity of MORC2 be required to mediate chromatin 
compaction during HUSH-mediated repression in vivo, disruption of MORC2 should 
result in a more open chromatin structure at sites of HUSH activity. ATAC-seq is 
currently a leading method to assay changes in chromatin accessibility in vivo26, but 
our attempts to exploit this technology to examine potential chromatin decompaction 
in MORC2 knockout HeLa cells were hampered by a large proportion of contaminating 
mitochondrial reads27 and insufficient coverage of the heterochromatic portions of the 
genome at which HUSH functions (Supplementary Fig. 5a,b). We therefore developed 
a new approach, Differential Viral Accessibility (DIVA), to examine changes in 
chromatin accessibility in vivo. DIVA is conceptually similar to ATAC-seq, but, rather 
than identifying transposon integration sites to probe accessible chromatin, DIVA 
maps the integration sites of exogenous lentiviruses (Fig. 4c and Supplementary Fig. 
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5c). In contrast to the Tn5 transposase which preferentially integrates near 
transcriptional start sites, HIV-1-derived lentiviral vectors preferentially target gene 
bodies28.  
We used DIVA to compare chromatin accessibility in wild-type and MORC2-null 
HeLa cells. Approximately 20 million independent viral integration sites were mapped 
in each cell type, and the two datasets were then compared to identify loci exhibiting 
significantly greater numbers of integrations in the MORC2 knockout cells compared 
to the parental wild-type cells (Fig. 4c and Supplementary Fig. 5d-g). Considering the 
genome as a series of 10 kb windows, we identified 278 loci exhibiting chromatin 
decompaction upon knockout of MORC2 (Fig. 4d and Supplementary Table 2). A large 
proportion of these loci were heterochromatic sites at which TASOR or MORC2 
occupancy was observed by ChIP-seq (Fig. 4e). Notably, many of these loci contained 
zinc finger (ZNF) genes (Fig. 4f), and, on the ZNF-rich chromosome 19, for example, 
a striking concordance was observed between the positions of ZNF gene clusters and 
the loci exhibiting decompaction in MORC2 knockout cells (Fig. 4g). Employing an 
orthogonal technique based on micrococcal nuclease sensitivity, we validated 
increased chromatin accessibility in MORC2 knockout cells at four example ZNF loci 
(Supplementary Fig. 6). 
 
MORC2 knockout results in chromatin decompaction, decreased H3K9me3 and 
transcriptional derepression. 
We also wanted to assess the relationship between MORC2-dependent 
changes in chromatin accessibility and H3K9me3 deposition. We found that loss of 
MORC2 in HeLa cells resulted in a decrease in H3K9me3 at the vast majority of loci 
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exhibiting chromatin decompaction upon MORC2 knockout (Fig. 5a,b and 
Supplementary Fig. 7a), supporting the idea that chromatin decompaction also results 
in a concomitant decrease in H3K9me3 levels. Consistent with the functional 
association between MORC2 and the HUSH complex, 906 of the 918 loci (99%) that 
we previously found to have lost H3K9me3 upon deletion of either of the three HUSH 
subunits9 also showed decreased H3K9me3 levels in MORC2 knockout cells (Fig. 5c). 
At the vast majority of these sites, H3K9me3 deposition was dependent on the HUSH-
associated methyltransferase SETDB1 (Supplementary Fig. 7a,b).  
Finally we considered the effect of chromatin decompaction at these sites on 
gene expression. In addition to a decrease in H3K9me3, we found that decompaction 
following knockout of MORC2 resulted in an increase in the mean expression level of 
the 89 genes residing within these loci (Fig. 5d), with 42 genes (47%) displaying >1.2-
fold increase in expression. Furthermore, of all 190 genes significantly upregulated 
upon MORC2 knockout (Fig. 5e), ZNF genes represented the most significantly 
enriched functional group (Fig. 5f). Consistent with a repressive role for MORC2, the 
majority of the upregulated genes were direct targets of TASOR and/or MORC2 as 
assessed by ChIP-seq (Supplementary Fig. 7c,d), and many also exhibited a loss of 
H3K9me3 and decompaction upon MORC2 knockout (Supplementary Fig. 7e). In 
contrast, ablation of MORC2 did not result in a global transcriptional change across 
genes exhibiting HUSH-independent MORC2 occupancy at their TSSs 
(Supplementary Fig. 7f). Altogether, these data support a model whereby loss of 
MORC2 results in chromatin decompaction, a loss of SETDB1-mediated H3K9me3 




 The R252W CMT mutation in MORC2 hyper-activates HUSH silencing.  
Five independent studies have recently reported that dominant mutations in the 
ATPase domain of MORC2 can cause axonal Charcot-Marie-Tooth (CMT) disease 
(Fig. 6a)29–33. We focused on understanding the functional impact of the most 
prevalent mutation, an arginine to tryptophan substitution at residue 252 (R252W or 
p.Arg252Trp in Uniprot: Q9Y6X9-1), which results in a severe axonal form of CMT230. 
This is the identical mutation to the reported R190W variant of MORC229,31,32, which 
refers to a putative alternative isoform of the protein (Uniprot: Q9Y6X9-2) that lacks 
62 amino acids at the N-terminus.  
Consistent with the genetic data which suggests a gain-of-function mechanism 
underlying the pathogenicity of the mutations, MORC2 harboring the R252W mutation 
did encode a functional protein capable of restoring HUSH-mediated transgene 
repression in MORC2 knockout HeLa cells (Fig. 6b,c). Moreover, the R252W mutant 
consistently outperformed the wild-type protein, resulting in enhanced re-repression 
of the GFP reporter. Indeed, despite being expressed at a lower level that the wild-
type protein, the R252W mutation both accelerated the rate of reporter re-repression 
and enhanced the overall degree of reporter repression observed (Fig. 6d and 
Supplementary Fig. 8). To verify that this effect was also observed at endogenous 
genes targeted by HUSH and MORC2, we performed RNA-seq analysis to compare 
the transcriptome of MORC2 knockout HeLa cells reconstituted with wild-type MORC2 
versus the R252W mutant (Supplementary Fig. 9). In agreement with the results from 
the reporter assays, we found that the R252W mutation resulted in the hyper-
repression of MORC2 target genes (Supplementary Fig. 9).  
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The mutant MORC2 proteins exert a dominant effect in CMT patients, driving 
the disease phenotype when co-expressed with a wild-type MORC2 allele. Therefore, 
we considered whether the R252W mutant MORC2 could hyper-repress HUSH target 
genes when expressed alongside the wild-type protein in MORC2-sufficient cells. 
First, we found that overexpression of R252W MORC2, but not wild-type, resulted in 
hyper-repression of a HUSH-responsive “GFPdim” HeLa reporter clone that exhibited 
weak expression at steady state (Fig. 6e). We then considered whether this effect 
would also occur at endogenous genes in neuronal cells. Transcriptome analysis of 
SK-N-SH neuroblastoma cells by RNA-seq (Fig. 6f) showed that overexpression of 
either wild-type or R252W MORC2 enhanced repression at example HUSH target 
sites (Fig. 6g); however, this effect was substantially greater with the R252W mutant, 
despite it being expressed at ~7.5-fold lower levels than the wild-type protein (Fig. 6h). 
Indeed, of the 91 genes significantly over-repressed by R252W compared to the wild-
type protein, 31 (34%) were ZNF genes marked by H3K9me3 (Fig. 6i). Overall these 
data suggested that the R252W mutation in MORC2 can hyper-activate HUSH-
mediated epigenetic repression, resulting in over-repression of HUSH target genes in 










The recently-identified HUSH complex is an important regulator of mammalian 
heterochromatin that is critical for silencing of newly-integrated retroviruses9 and for 
normal embryonic development12,13. Here, through a genome-wide CRISPR/Cas9-
mediated forward genetic screen, we have identified MORC2 as an additional 
accessory member of the HUSH complex. MORC2 is recruited by the HUSH complex 
to heterochromatic loci, where its ATPase activity is essential for HUSH-mediated 
silencing. Exploiting a new method, Differential Viral Accessibility (DIVA), we found 
that loss of MORC2 resulted in chromatin decompaction at these sites, accompanied 
by a decrease in H3K9me3 levels and transcriptional derepression. Furthermore, we 
show that the most commonly identified Charcot-Marie-Tooth disease mutation in the 
MORC2 ATPase domain, R252W, results in hyper-activation of HUSH-mediated 
repression at heterochromatic loci.   
  Previously we identified the HUSH complex through a gene-trap mutagenesis 
screen in the near-haploid KBM7 human cell line9. The rapid emergence of 
CRISPR/Cas9-mediated genome editing technologies has now allowed us to 
reexamine the complement of genes required for transgene repression, using a 
genome-wide library of sgRNAs to create the starting pool of mutant cells. The results 
of the two screens proved to be complementary, as, although the CRISPR screen 
failed to identify two of the core HUSH complex subunits detected by the original 
haploid gene-trap screen, it did reveal an essential role for one additional gene, 
MORC2 (Fig. 1). The CRISPR screening technique therefore represents a powerful 
alternative to the haploid gene-trap approach14, and, with considerable interest in the 
design of more efficacious guide RNA libraries34–36, it is likely that the accuracy of such 
genome-wide CRISPR screens will continue to improve.   
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In humans, the MORC protein family comprises four proteins (MORC1-4) plus 
the more divergent SMCHD119. MORC1 represses transposable elements in the male 
mouse germ line21 and MORC2 has been implicated in the response to DNA 
damage25, but the molecular function of the mammalian MORC family members 
remains largely uncharacterized. All MORC proteins share a similar domain 
architecture, comprising an N-terminal GHKL-type ATPase domain and a CW-type 
zinc finger, but their functions are likely to be distinct. For example, the inability of the 
CW-type zinc fingers of MORC1 and MORC2 to recognize methylated H3K4 suggests 
a different mode of recruitment to chromatin compared to MORC3 and MORC422, 
whilst it is only mutations in MORC2 that are associated with CMT disease29–33. A key 
challenge, therefore, is to elucidate how MORC proteins are recruited to chromatin 
and to determine their effect on nucleosomal architecture at target sites. Here we 
demonstrate that HUSH regulates the localization of MORC2 to target sites on 
chromatin, and that the ATPase activity of MORC2 plays a critical role in altering 
chromatin architecture at these sites during HUSH-mediated silencing.  
The ATPase activity of MORC2 is required to drive nucleosome remodeling in 
vitro25, and was essential for transgene silencing by the HUSH complex in vivo (Fig. 
4a,b). Therefore, it followed that the remodeling activity of MORC2 might be required 
to alter chromatin architecture at these sites to promote gene silencing. Although 
ATAC-seq has been widely used to study the degree of chromatin “opening” at 
transcriptional start sites, we found it unsuitable to probe decompaction of 
heterochromatic regions due to the low proportion of transposon integrations into such 
sites. Instead of mapping transposon integration sites, DIVA examines the integration 
preferences of exogenous lentiviruses to probe accessible chromatin. Lentiviruses 
preferentially target the bodies of genes28, and indeed our data show that this 
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approach affords far greater coverage of the heterochromatic sites at which the HUSH 
complex functions. We therefore anticipate that DIVA may prove a useful approach to 
interrogate changes in heterochromatin structure in vivo in other experimental 
systems. However DIVA may not be suitable for comparisons between non-isogenic 
cell lines, where it may be impossible to control for differences in the abundance or 
activity of other factors influencing viral integration preferences. Furthermore DIVA 
relies on high-efficiency transduction with lentiviral vectors, which may not be 
achievable in all cell types, and, compared to the simplicity of ATAC-seq, requires a 
more involved protocol for the preparation of sequencing libraries to map virus-
genome junctions. 
Our application of DIVA to compare wild-type and MORC2-null cells revealed 
that loss of MORC2 resulted in chromatin decompaction at HUSH target sites. The 
repetitive ZNF gene family represented the most enriched functional group. Many of 
the ZNF genes are located in clusters covered by high levels of H3K9me3, which also 
coats other repetitive regions of the genome, including centromeres and tandem 
repeats. While we did not observe decompaction of these additional repetitive regions 
upon MORC2 disruption, we do not know how well DIVA will capture these other sites 
of repressive heterochromatin. Further experiments will be needed to address the 
specific physiological role of MORC2 with HUSH and SETDB1 in maintaining 
H3K9me3 across the body of ZNF genes.  
 The DIVA results suggest that HUSH target loci normally adopt a compact 
chromatin state which needs to be reversed to alleviate repression. Although 
repressed genomic regions have canonically been associated with dense chromatin 
domains that are refractory to the transcription machinery, there may be distinct 
mechanisms through which such nucleosome compaction is achieved. In particular, 
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the specific requirement for ATP hydrolysis to drive compaction during HUSH-
mediated silencing seems to be distinct from other key repressive complexes. For 
example, ATP hydrolysis has not been implicated in heterochromatin formation 
through the SUV39H1-HP1 axis, another major route to H3K9me3-mediated silencing. 
Compact heterochromatic structures have also been associated with Polycomb-driven 
repression37, but again this compaction function does not seem to require an ATP 
motor and has instead been attributed to a disordered region rich in basic amino acids 
in PRC138. However, ATP-dependent chromatin remodelers have previously been 
shown to play an indirect role in transcriptional repression by establishing the 
appropriate nucleosome spacing for subsequent silencing39. For example, the 
Nucleosome Remodeling Deacetylase (NuRD) complex utilizes the chromatin 
remodeling function of its CHD subunits to space adjacent nucleosomes, thereby 
making the histone tails accessible for deacetylation40. Therefore, one possibility is 
that MORC2 is recruited by HUSH to position nucleosomes in a manner that renders 
the chromatin permissive to transcriptional repression. 
 The mechanism through which dominant mutations in MORC2 cause axonal 
CMT disease29–33 and severe spinal muscular atrophy (SMA)-like disease41 is 
unknown. Given that these patients retain one functional wild-type MORC2 allele, the 
disease phenotype is unlikely to result from loss-of-function of the mutant protein. Our 
data suggest that a gain-of-function effect underlies the phenotype of the MORC2 
R252W CMT mutation, which results in hyper-activation of HUSH complex function at 
both exogenous transgenes and endogenous genomic loci. Indeed, the closely-related 
MORC1 protein – which represses transposable elements in the male germ line21 – 
contains a tryptophan residue at the equivalent position. 
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Further work will be required to elucidate the biochemical basis underlying the 
hyper-activation phenotype resulting from the MORC2 R252W mutation. Structural 
insight into the organization of the MORC2 ATPase domain would be invaluable in 
assessing the impact of the R252W mutation, and may also guide the rational design 
of small molecule inhibitors. Inhibition of Hsp90, the prototypical member of the GHKL-
family of ATPases, has been successfully achieved using the small molecules 
geldanamycin and radicicol42,43, and the latter is also effective against the distantly-
related GHKL-family member SMCHD144. Overall, these data suggest that inhibition 
of the ATPase domain of MORC2 provides an attractive target for the therapeutic 
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Figure 1. A genome-wide CRISPR/Cas9-mediated forward genetic screen 
identifies an essential role for MORC2 in transgene silencing by the HUSH 
complex. (a,b) A genome-wide CRISPR screen to identify genes required for 
transgene silencing. Cas9 was expressed in a population of GFPdim KBM7 cells 
harboring epigenetically repressed transgenes, and genome-wide mutagenesis 
carried out using the GeCKO v2 sgRNA library (a). Mutant GFPbright cells containing 
gene disruption events that prevented reporter repression were isolated through two 
sequential rounds of FACS (b). Black boxes indicate approximate sorting gates. (c) 
Bubble plot illustrating the hits from the screen. All genes targeted by sgRNAs are 
arranged alphabetically by gene name on the x-axis, with their statistical significance 
as determined by the RSA algorithm plotted on the y-axis. Bubble size is proportional 
to the number of active sgRNAs for each gene. Colored bubbles represent validated 
hits; the HUSH complex subunits TASOR and Periphilin (black) did not reach statistical 
significance, while SEL1L (orange) is involved in the degradation of the GFP fusion 
protein14. A fully annotated plot is provided in Fig. S1. (d,e) MORC2 is required for 
transgene silencing by the HUSH complex in HeLa cells. CRISPR/Cas9-mediated 
disruption of MORC2 results in derepression of a HUSH-repressed reporter as 







Figure 2. The ATPase, CW and coiled-coil domains of MORC2 are required for 
HUSH complex function. (a) Schematic representation of the domain structure of 
MORC2. (CC, predicted coiled-coil; S5, ribosomal S5-like domain; CW, CW-type zinc 
finger; CD, chromo-like domain) (b-d) Generation and validation of MORC2 knockout 
HeLa cells. A HeLa reporter clone harboring a HUSH-repressed GFP reporter was 
transfected with a pool of plasmids to express Cas9 and three sgRNAs targeting 
MORC2. Cells in which the MORC2 gene was disrupted became GFP+ owing to 
derepression the GFP reporter and were isolated using FACS (b). The sorted GFP+ 
population no longer expressed MORC2 protein as assessed by immunoblot (c). 
MORC2 knockout single cell clones were then isolated from the GFP+ sorted 
population (d). (e,f) Assessing the domains required for MORC2 function through the 
genetic complementation of MORC2 knockout cells. Expression of wild-type MORC2 
or a MORC2 mutant lacking the chromodomain (ΔCD) in MORC2 knockout cells 
resulted in re-repression of the GFP reporter transgene. In contrast, MORC2 variants 
lacking the ATPase, S5, CW or coiled-coil domains were non-functional and did not 
rescue HUSH-mediated repression (e). Immunoblot validation of expression of the 
MORC2 deletion mutants (f). All MORC2 variants were expressed with an N-terminal 
V5 epitope tag followed by an exogenous SV40 nuclear localization signal; detailed 








Figure 3. The HUSH complex recruits MORC2 to heterochromatic target sites. 
(a) MORC2 interacts with the HUSH complex. TASOR and MPP8 co-
immunoprecipitate with V5-tagged MORC2 expressed in HeLa cells. (b) Summary of 
MORC2 genome occupancy as measured by ChIP-seq. In total 4500 peaks of V5-
MORC2 occupancy were detected, the majority of which fell into two categories: 
binding sites in heterochromatin marked by H3K9me3 (purple; left) and binding sites 
at transcriptional start sites (green; right). (c,d) The HUSH complex recruits MORC2 
to heterochromatic sites marked by H3K9me3. TASOR and MORC2 occupancy was 
observed at a range of sites marked by H3K9me3; MORC2 recruitment at these sites 
was HUSH-dependent, as V5-MORC2 occupancy was lost in cells lacking all three 
HUSH subunits9 (HUSH KO). Three example loci are shown in (c), with summary data 
across all loci shown in (d). Full ChIP-seq traces including input DNA controls are 
shown in Supplementary Fig. 3a. (e,f) MORC2 recruitment to transcriptional start sites 
is independent of the HUSH complex. MORC2 occupancy was observed at a large 
number of transcriptional start sites (TSSs) marked by the H3K4me3 histone 
modification. This was independent of the HUSH complex, as TASOR occupancy was 
not observed at these sites and MORC2 occupancy was maintained in cells lacking 
HUSH subunits. Three example loci are shown in (e), with summary data across all 
loci shown in (f). Full ChIP-seq traces including input DNA controls are shown in 






Figure 4. Loss of MORC2 results in chromatin decompaction at HUSH target 
sites. (a,b) ATP hydrolysis by MORC2 is critical for HUSH-mediated transgene 
repression. Exogenous expression of MORC2 mutants unable to bind (N39A) or 
hydrolyze (D68A) ATP failed to rescue reporter repression in MORC2 knockout cells 
(a). Immunoblot validation of expression of the MORC2 point mutants (b). (c) Overview 
of the DIVA methodology, which utilizes large-scale mapping of lentiviral integration 
sites to probe accessible chromatin. See Supplementary Figure 5c,d for more details. 
(d) Loss of MORC2 results in chromatin decompaction. Scatter plot highlighting the 
289 genomic loci (orange) which exhibit increased accessibility in MORC2 knockout 
cells. Unique lentiviral integration sites mapped to the ZNF772 locus in wild-type and 
MORC2 knockout cells are shown as an example. DIVA scores for all genomic loci 
are detailed in Supplementary Table 2. (e) The majority of loci exhibiting decompaction 
upon MORC2 knockout are direct targets of MORC2 and the HUSH complex. Of the 
278 decompacted loci, MORC2 and/or TASOR occupancy can be detected at 199 loci 
(71%). (f,g) Loci exhibiting decompaction upon MORC2 knockout are highly enriched 
for ZNF genes (f), and the decompacted regions across chromosome 19 correspond 








Figure 5. Chromatin decompaction in MORC2 knockout cells is accompanied by 
a loss of H3K9me3 and transcriptional depression. (a,b) H3K9me3 is lost across 
the majority of loci exhibiting decompaction upon MORC2 knockout. Of the 278 
decompacted loci, a loss of H3K9me3 upon MORC2 knockout in HeLa cells was 
observed at 220 loci (79%), as measured by ChIP-seq (a). Summary data across all 
278 decompacted loci is shown in (b). (c) Knockout of MORC2 results in loss of 
H3K9me3 at the same sites which lose H3K9me3 upon knockout of HUSH subunits. 
Previously we identified 918 genomic loci in HeLa cells that lose H3K9me3 upon 
knockout of either TASOR, MPP8 or Periphilin (green dots)9; these same loci also 
exhibited decreased H3K9me3 levels upon knockout of MORC2. (d,e) The effect of 
knockout of MORC2 on the transcriptome. RNA-seq analysis was performed to 
compare the transcriptome of wild-type and MORC2 knockout HeLa cells. In (d), 
genes residing in loci exhibiting decompaction in MORC2 knockout cells (n = 89) are 
highlighted in red; loci exhibiting decompaction also exhibit increased expression as 
measured by RNA-seq (inset). In (e), all genes exhibiting significantly altered 
expression between wild-type and MORC2 knockout cells (n = 462; DEseq P < 0.05) 
are highlighted in orange. (f) Functional classification of the genes upregulated in 
MORC2 knockout cells using the DAVID functional annotation tool. Genes upregulated 







Figure 6. The R252W mutation in MORC2 associated with Charcot-Marie-Tooth 
disease hyper-activates HUSH-mediated epigenetic repression. (a) Schematic 
representation of the mutations associated with CMT affecting the ATPase domain of 
MORC2. (b,c) Assessing the effect of the R252W CMT mutation on MORC2 function 
through genetic complementation of MORC2 knockout cells. The R252W CMT mutant 
MORC2 is functional, restoring HUSH-mediated transgene silencing when expressed 
in MORC2 knockout cells (b). Immunoblot validation of expression of wild-type or 
R252W mutant MORC2 (c). (d,e) The R252W CMT mutation in MORC2 hyper-
activates HUSH-mediated transgene silencing in HeLa cells. Time-course of 
transgene re-repression in MORC2 knockout HeLa cells (d): the R252W MORC2 
mutant increases both the rate and overall extent of transgene re-repression. Hyper-
repression of a GFPdim HUSH reporter in MORC2-sufficient cells by over-expression 
of R252W MORC2 (e). (f) Schematic representation of the RNA-seq experiment in 
wild-type SK-N-SH neuroblastoma cells. (g – i) Expression of either wild-type MORC2 
or the R252W mutant results in hyper-repression of HUSH target genes. RNA-seq in 
SK-N-SH cells overexpressing either wild-type or R252W MORC2 reveals hyper-
repression of example HUSH target genes (g); despite R252W MORC2 being 
expressed at a much lower level than the wild-type protein (h), this effect was more 
pronounced with the R252W mutant. In total, 91 genes were hyper-repressed by the 








Cell culture. HeLa cells were obtained from ECACC and were grown in RPMI 1640 
plus 10% fetal calf serum (FCS) and penicillin/streptomycin (100 U/ml); approximate 
doubling time was 22-23 hours for both wild-type cells all derivative cell lines. KBM7 
cells, obtained from Dr. Brent Cochran7, and HEK 293ET cells, a gift from Dr. Felix 
Randow, and were cultured in IMDM plus 10% FCS and penicillin/streptomycin (100 
U/ml). SK-N-SH cells were a gift from Prof. David Rubinsztein and were grown in 
DMEM plus 10% FCS and penicillin/streptomycin (100 U/ml); approximate doubling 
time was 55-60 hours for both wild-type cells and all derivative cell lines. All cell lines 
were routinely tested for mycoplasma contamination (ATCC Universal Mycoplasma 
Detection Kit). 
 
Antibodies. The following primary antibodies were used: rabbit α-MORC2 (Bethyl 
Laboratories, A300-149A used for immunoblot), rabbit α-MORC2 (Santa Cruz 
Biotechnology, sc-366271, used for immunofluorescence), rabbit α-TASOR (Atlas 
Antibodies, HPA006735), rabbit α-MPP8 (Proteintech, 16796-1-AP), rabbit α-SETDB1 
(Proteintech, 11231-1-AP), mouse α-GFP (Life Technologies, A11120), mouse α-V5 
(Abcam, ab27671), rabbit α-V5 (Abcam, ab15828), goat α-Lamin B1 (Santa Cruz, sc-
6217), rabbit α-H3K9me3 (Abcam, ab8898), rabbit α-Histone H3 (Biolegend, 601902), 
rabbit IgG (Cell Signaling, #2729), mouse α-calnexin (AF8, a kind gift from M. Brenner, 
Harvard Medical School) and mouse α-β-actin (Sigma-Aldrich, A5316). Alexa Fluor 
488- and Alexa Fluor 546-conjugated secondary antibodies for immunofluorescence 
were obtained from Molecular Probes. HRP-conjugated secondary antibodies for 




CRISPR/Cas9-mediated forward genetic screen. Previously we generated a 
polyclonal population of GFPdim KBM7 cells harboring epigenetically-repressed 
transgenes through lentiviral transduction with a vector expressing a GFP-fusion 
protein from the SFFV LTR promoter (pHRSIN-PSFFV-GFP-HLA-A2). The Cas9 
nuclease was stably expressed in this population through lentiviral transduction 
followed by hygromycin selection (500 μg/ml). One hundred million Cas9-expressing 
reporter KBM7 cells were transduced with the GeCKO v2 sgRNA library at a 
multiplicity of infection of ~0.1 and untransduced cells removed from the population 
through puromycin selection (0.75 μg/ml) commencing 48 hours post-transduction. 
GFPbright cells resulting from the mutagenesis were enriched by two rounds of FACS, 
with the first sort taking place 7 days post-mutagenesis and the second sort taking 
place a further 7 days later. Genomic DNA was extracted (Gentra Puregene Kit) from 
the selected GFPbright cells after the second sort together with a representative sample 
of the unsorted mutagenized library that had been grown in parallel for the equivalent 
amount of time.  
 The abundance of sgRNAs in each sample was quantified by Illumina 
sequencing. The variable region of the sgRNAs was amplified in a nested PCR 
reaction (Q5 High-Fidelity Polymerase, NEB) with forward primers binding the U6 
promoter region and reverse primers binding the constant region of the sgRNA. For 
PCR1, 32 x 100 μl reactions each using 4 µg of DNA were performed for the 
unselected library sample, and 32 x 100 μl reactions each using 4 µg of DNA were 
performed for selected cells sample. The products of these reactions were pooled, 
one-tenth was purified using Agencourt AMPure XP beads (Beckman Coulter), and 
one-tenth of resulting DNA was used as a template for 12 cycles of PCR2 with Illumina 
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P5- and P7- adapted primers. Following a further AMPure XP bead purification, PCR 
products were quantified, pooled and sequenced on an Illumina HiSeq 2500 
instrument using 50 bp single-end reads from a custom primer binding immediately 
upstream of the sgRNA sequence. All primer sequences are detailed in 
Supplementary Table 3. 
 The resulting sequence reads were trimmed of the constant portion of the 
sgRNA using the fastx toolkit, and then aligned to an index of the GeCKO v2 library 
using Bowtie 2. Uniquely aligning reads were used to generate sgRNA count tables 
for each sample, which were analyzed further using the RSA algorithm to identify 
genes significantly enriched for gene disruption events in the selected cells versus the 
unselected library.   
 
Individual CRISPR/Cas9-mediated gene disruption. Oligonucleotides (Sigma-
Aldrich) for top and bottom strands of the sgRNA were phosphorylated with T4 PNK 
(NEB), annealed by heating to 95ºC followed by slow cooling to room temperature, 
and then cloned into either the dual Cas9/sgRNA expression vector pSpCas9(BB)-2A-
Puro (Addgene #48139, kindly deposited by Dr. Feng Zhang45) or the lentiviral sgRNA 
expression vector pKLV-U6gRNA(BbsI)-PGKpuro2ABFP (Addgene #50946, kindly 
deposited by Dr. Kosuke Yusa46).  
 
Lentiviral expression. Exogenous gene expression was achieved using the 
expression vectors pHRSIN-PSFFV-GFP-PPGK-Hygro, pHRSIN-PSFFV-GFP-IRES-
mCherry-PPGK-Hygro and pHRSIN-PSFFV-GFP-PPGK-Blasto, with the gene of interest 
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inserted in place of GFP. For lentiviral expression of shRNA constructs, the pHR-
SIREN vector was used with hairpins cloned in as BamHI-EcoRI fragments. In all 
cases, lentivirus was generated through the triple transfection of HEK 293ET cells with 
the lentiviral transfer vector plus the two packaging plasmids pCMVΔR8.91 and 
pMD.G using TransIT-293 transfection reagent (Mirus) according to the 
manufacturer’s recommendations. Viral supernatant was typically harvested 48 h 
post-transfection, cell debris removed using a 0.45 µm filter, and target cells 
transduced by spin infection at 800 x g for 60 min. Transduced HeLa cells were 
selected with the following drug concentrations: puromycin, 2 μg/ml; hygromycin 50 
μg/ml; blasticidin, 3 μg/ml. Transduced SK-N-SH cells were selected using 50 μg/ml 
hygromycin.     
 
Flow cytometry. Cells were fixed in 1% PFA and analyzed on a FACSCalibur (BD) or 
a FACSFortessa (BD) instrument. Data was analyzed using FlowJo software. For cell 
sorting, cells were resuspended in PBS + 2% FCS and FACS was carried on an Influx 
cell sorter (BD). 
 
Immunofluorescence. HeLa cells were grown overnight on glass coverslips, fixed 
with the addition of 4% PFA for 10 minutes, permeabilized with 0.5% Triton X-100 for 
5 minutes, and then blocked for at least 30 min using 4% BSA dissolved in PBS + 
0.1% Tween-20 (PBS-T). The primary antibody was diluted in 40 µl of blocking solution 
and was applied for 1 h, and, following five washes in PBS-T, fluorophore-conjugated 
secondary antibody (Molecular Probes) was applied for 45 min in the same way. 
Following a further five washes in PBS-T and a final rinse in distilled water, coverslips 
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were mounted in 4 µl ProLong Gold Antifade Mountant with DAPI (Thermo Fisher 
Scientific) and imaged using a Nikon LSM880 laser scanning confocal microscope 
(Zeiss). Images were processed using Adobe Photoshop (Adobe, CA) or GIMP 2.  
 
Co-immunoprecipitation. Cells were washed once in PBS and then lysed in cell lysis 
buffer (0.5% IGEPAL, 85 mM KCl and 10 mM HEPES in distilled water). Nuclei were 
harvested by centrifugation at 800 x g for 5 minutes at 4ºC, and then lysed in nuclear 
lysis buffer (1% IGEPAL plus 1:100 Benzonase in TBS). Insoluble nuclear material 
was removed by centrifugation (10,000 x g for 5 minutes at 4ºC) and then the 
supernatant was pre-cleared with protein G magnetic beads (Thermo Fisher Scientific) 
for 1 h at 4°C. Immunoprecipitation was performed by adding 1 µg of antibody and 
protein G magnetic beads for 2 h at 4°C, and, following three washes of the beads in 
lysis buffer, samples were eluted in SDS sample buffer.  
 
Immunoblotting. Cells were lysed in 1% SDS plus 1:100 Benzonase (Sigma-Aldrich) 
for 20 minutes at room temperature, and then heated to 70°C in SDS sample buffer 
for 10 min. Following separation by SDS-PAGE, proteins were transferred to a PVDF 
membrane (Millipore) which was then blocked in 5% milk in PBS + 0.2% Tween-20. 
Membranes were probed overnight with the indicated antibodies, washed three times 
PBS + 0.2% Tween-20, and then incubated with HRP-conjugated secondary 
antibodies (Jackson ImmunoResearch) for 45 minutes at room temperature. Reactive 
bands were visualized using SuperSignal West Pico or West Dura (Thermo Fisher 
Scientific). All blots presented in the figures have been cropped; the original uncropped 




Subcellular fractionation. One million cells were washed in PBS and then again in 
Buffer A (10 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT and an EDTA-free 
protease inhibitor cocktail tablet (Roche)). The cells were then lysed upon 
resuspension in Buffer A plus 0.1% (v/v) IGEPAL on ice for 10 min. Nuclei were 
pelleted by centrifugation (1400 x g for 4 min at 4°C) and the supernatant, which 
contains the cytosolic fraction, was collected. The nuclear pellet was resuspended in 
Buffer B (20 mM HEPES, 1.5 mM MgCl2, 300 mM NaCl, 0.5 mM DTT, 25% v/v glycerol, 
0.2 mM EDTA and an EDTA-free protease inhibitor cocktail tablet) for 10 min on ice, 
and, following centrifugation at 1700 x g for 4 min at 4°C, the supernatant (containing 
the nucleosolic fraction) was removed. The insoluble pellet, constituting the chromatin 
fraction, was subsequently solubilized in 1% SDS plus 1:100 Benzonase for 20 min at 
room temperature.   
 
ChIP-seq. Cells were washed once in PBS, resuspended in growth medium, and then 
cross-linked in 1% formaldehyde for 10 min. The reaction was quenched by adding 
glycine to a final concentration of 0.125 M for 5 min before the cells were lysed in cell 
lysis solution (1 mM HEPES, 85 mM KCl, 0.5% IGEPAL). Nuclei were pelleted by 
centrifugation, and then resuspended in nuclear lysis solution (5 mM Tris, 10 mM 
EDTA, 1% SDS) for 10 min. The chromatin was sheared using a Bioruptor 
(Diagenode; high power, 20 cycles of 30 s on, 30 s off) to obtain a mean fragment size 
of ~300 bp. Insoluble material was removed by centrifugation. The chromatin solution 
was pre-cleared with protein A sepharose (Sigma-Aldrich) and then 
immunoprecipitated overnight using 5 µg primary antibody and protein A sepharose, 
or, for V5-MORC2, anti-V5 agarose affinity gel (Sigma-Aldrich, A7345). The next day 
the beads were washed a total of five times, and then bound protein-DNA complexes 
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eluted in 150 mM NaHCO3 and 1% SDS. Cross-links were reversed by overnight 
incubation at 67ºC with 0.3 M NaCl and RNaseA. Proteinase K was then added and 
the samples incubated for 2 h at 45ºC, and then the DNA was purified using a spin 
column (Qiagen PCR purification kit). Illumina sequencing libraries were produced 
from this material using the TruSeq ChIP sample prep kit (Illumina), and 50 bp single-
end reads generated on a HiSeq 2500 instrument. Reads were aligned to the human 
genome (GRCh37) using Bowtie 2, and reads with a MAPQ score >10 were imported 
into SeqMonk and EaSeq47 for further analysis. V5-MORC2 binding sites were 
identified using the implementation of the MACS peak caller in SeqMonk (windows 
size = 300 bp; p-value < 0.0001) and the resulting 4500 peaks were centered and 
plotted using the Average Signal Tracks tool in EaSeq. H3K4me3 ChIP-seq data 
generated by the Bernstein laboratory was downloaded from the ENCODE project 
(ENCSR000AOF). 
  
qRT-PCR. RNA was prepared using the RNeasy Plus kit (Qiagen) and converted into 
cDNA using Super RT reverse transcriptase (HT Biotechnology) and a poly(dT) 
primer. Quantification by qPCR was performed on an ABI 7500 Real Time PCR 
System (Applied Biosystems) using SYBR green PCR mastermix (Life Technologies) 
in a final reaction volume of 25 μl. Thermal cycling parameters were: 50°C for 2 min; 
95°C for 5 min; 40 cycles of 95°C for 15 s and 58°C for 1 min. Error bars represent the 
standard deviation of at least three technical replicates. Primer sequences are detailed 




Expression and purification of the CW domain of MORC2. A synthetic, E. coli 
codon-optimized DNA construct (IDT) encoding the MORC2 CW domain (residues 
490-546) plus a C-terminal FLAG tag was cloned into the expression vector pET-28a-
N-His-SUMO between the BamHI and NotI restriction sites for production of the N-
terminally His-SUMO-tagged protein product. Protein was produced in E. coli 
BL21(DE3) cells through overnight incubation at 18 ºC with shaking at 220 rpm 
following induction with 200 µM IPTG. Cell pellets were resuspended in 30 ml lysis 
buffer (50 mM Tris-HCl, 500 mM NaCl, 10 mM imidazole, 0.1 mM ZnSO4, 1 mM DTT, 
1x Complete EDTA-free protease inhibitors, pH 8.0), flash frozen in liquid nitrogen and 
stored at -80 ºC. 
Pellets were thawed and further lysed by sonication on ice, before clarification 
by centrifugation (45 min, 40,000 x g, 4ºC). The resulting His-SUMO-CW-FLAG-
containing supernatant was subjected to immobilized Ni-NTA affinity chromatography 
with wash (50 mM Tris.HCl, 500 mM NaCl, 10 mM imidazole, 0.1 mM ZnSO4, 
1 mM DTT, pH 8.0) and elution (50 mM Tris.HCl, 500 mM NaCl, 300 mM imidazole, 
0.1 mM ZnSO4, 1 mM DTT, pH 8.0) buffers, and then desalted using a Bio-Rad Econo-
Pac 10DG column into cleavage buffer (20 mM HEPES, 150 mM NaCl, 0.1 mM ZnSO4,  
1 mM DTT, pH 7.4). The His-SUMO tag was cleaved from the protein by the addition 
of His-tagged SENP1 protease (1:10 w/w) for 18 h on ice. Subtractive immobilized Ni-
NTA affinity chromatography was then used to deplete the tagged protease and the 
free His-SUMO tag, and the protein was further purified by size exclusion 
chromatography on a Superdex 75 (10/300) column in a buffer containing 20 mM 
HEPES, 200 mM NaCl, 0.1 mM ZnSO4, 1 mM TCEP, pH 7.3. The mass of the intact, 




Differential Viral Accessibility (DIVA). Six million wild-type and MORC2 knockout 
HeLa cells were seeded at a density of 1x106 cells per well of a 6-well plate, and 
transduced on successive days with the lentiviral vector pHRSIN-PSFFV-mCherry-
WPRE (encoding the mCherry fluorescent protein driven by the spleen focus-forming 
virus LTR promoter) at high multiplicity of infection such that ~100% of the cells were 
mCherry+. One day after the second transduction genomic DNA was extracted (Gentra 
Puregene Kit) and digested overnight with NlaIII (NEB). The distribution of NlaIII sites 
in the lentiviral vector is such that DNA fragments smaller than ~1.8 kb cannot contain 
viral-genome junctions; large fragments were therefore enriched through a size-
selection step using a 0.5x Agencourt AMPure XP bead clean-up (Beckman Coulter). 
An annealed dsDNA adaptor with an NlaIII-compatible overhang was then ligated onto 
the ends of the genomic DNA fragments using T4 DNA Ligase (NEB) overnight at 
16°C, and the ligated products purified through a further AMPure bead clean-up. Virus-
genome junctions were then amplified in 200 cycles of a linear PCR reaction using 
Accuprime Taq (Thermo Fisher Scientific) using a biotinylated primer binding the just 
upstream of the 5’ LTR in the integrated provirus, and the resulting products were 
annealed to streptavidin-coated M-280 dynabeads (Thermo Fisher Scientific). 
Following 5 x 10 minute washes with PBS + 0.1% Tween-20, virus-genome junctions 
were amplified through 12 cycles of on-bead exponential PCR reaction with an Illumina 
P5-adapted primer binding the proviral 5’LTR and a P7-adapted reverse primer 
binding the splinkerette adaptor. After a final AMPure XP clean-up, PCR products were 
quantified, pooled and sequenced on an Illumina HiSeq2500 instrument generating 50 
bp single-end reads from a custom primer annealing to the extreme end of the proviral 
5’ LTR. All oligonucleotide sequences are detailed in Supplementary Table 3. 
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 The resulting sequence reads were trimmed of adaptor sequences using the 
fastx toolkit and aligned to the human genome (hg19) using Bowtie 2. Reads with a 
MAPQ score > 10 were imported into SeqMonk and converted into a set of unique 
points of integration. The Intensity Difference Filter in Seqmonk was used to identify 
10 kb genomic windows (overlapping by 5 kb) significantly enriched for lentiviral 
integration sites in MORC2 knockout cells versus the parental wild-type cells; 
individual loci were only considered to exhibit decompaction if at least two adjacent 
windows reached statistical significance. Full data for all genomic loci is detailed in 
Supplementary Table 2. 
 
Micrococcal nuclease accessibility assay. Wild-type and MORC2 knockout HeLa 
cells were washed once in PBS, resuspended in growth medium, and then cross-
linked by the addition of 1% formaldehyde for 10 min. The reaction was quenched by 
addition of glycine to a final concentration of 0.125 M for 5 min. The cells were then 
lysed in cell lysis solution (1 mM HEPES, 85 mM KCl, 0.5% IGEPAL) and nuclei 
pelleted by centrifugation (800 x g, 5 min, 4°C). The nuclei (5 x 105 per reaction) were 
then resuspended in micrococcal nuclease buffer supplemented with BSA (NEB), and 
chromatin digested by the addition of 2 units of micrococcal nuclease (NEB) for 30 min 
at 37°C. EDTA was added to a final concentration of 45 mM to stop the reaction. Nuclei 
were then lysed in 1% SDS, RNA digested with RNaseA (37°C for 30 min) and cross-
links reversed overnight at 65°C. Proteins were then digested with proteinase K (37°C 
for 2 h) and DNA isolated by phenol-chloroform extraction followed by ethanol 
precipitation. Size-selection of the digested DNA was achieved using SPRIselect 
beads (Beckman Coulter) using 0.6 volumes of beads. The bound fraction contained 
large fragments (>~1000bp); the supernatant containing unbound fragments 
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(<~1000bp) was removed and subsequently purified by the addition of an extra 1 
volume of beads. The amount of DNA from target loci in the accessible and 
inaccessible fractions versus the pre-size-selected starting material was measured by 
qPCR performed on a CFX96 Touch Real-Time PCR machine (Bio-Rad) using iTaq 
Universal SYBR Green Supermix (Bio-Rad) in a final reaction volume of 25 μl. Thermal 
cycling parameters were: 50°C for 2 min; 95°C for 5 min; 40 cycles of 95°C for 15 s 
and 58°C for 1 min. Error bars represent the standard deviation of at least three 
technical replicates. Primer sequences are detailed in Supplementary Table 3. 
 
RNA-seq. Total RNA was extracted using the miRNEasy kit (Qiagen) as per the 
manufacturer’s instructions and multiplexed Illumina sequencing libraries were 
prepared using the TruSeq Stranded Total RNA Library Prep Kit (Illumina). For the 
comparison between wild-type and MORC2 knockout HeLa cells, ribosomal RNA was 
depleted using the Ribo-Zero Gold rRNA Removal Kit (Epicentre) and 150 bp paired-
end reads were generated on an Illumina HiSeq2500 instrument. For all comparisons 
between wild-type and R252W MORC2, polyA+ RNA was sequenced on an Illumina 
HiSeq2500 instrument using 50 bp single-end reads. Sequence reads were aligned to 
the human genome (GRCh37) using HISAT2. Mapped reads with a MAPQ score >40 
were imported into SeqMonk and further analyzed using the RNA-seq quantitation 
pipeline followed by DEseq2 or edgeR analysis.  
 
Statistics. No statistical methods were used to predetermine sample size. 
Experiments were not randomized and the experimenters were not blinded to the 
outcome. Genes significantly enriched for inactivating mutations in the CRISPR screen 
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were evaluated using the RSA algorithm comparing the frequency of sgRNAs in the 
GFPbright selected population versus the unselected mutangenized pool. All qRT-PCR 
data is represented as the mean +/- standard deviation of at least three technical 
replicates, and the data are representative of at least two independent experiments. 
For the RNA-seq data presented in Fig. 5e, three independent MORC2 knockout 
clones were used; genes exhibiting significantly altered expression in MORC2 
knockout cells were identified using the implementation of DEseq2 in Seqmonk (P < 
0.05). For the RNA-seq data presented in Fig. 6g-i, cells were transduced in triplicate 
with lentiviral vectors to express either wild-type or R252W mutant MORC2; genes 
exhibiting significantly reduced expression upon expression of the R252W mutant as 
compared to wild-type MORC2 were identified using the implementation of edgeR in 
Seqmonk (P < 0.05). 
 
Data availability. The sequence data from the CRISPR/Cas9 forward genetic screen, 
ChIP-seq, DIVA and RNA-seq experiments that support the findings of this study have 
been deposited in GEO with the primary accession code GSE95480. 

















Range of GFP 
expression 






















All genes targeted by sgRNAs 
FACS 2 
+ sg1-MORC2 
HUSH-repressed HeLa GFP reporter clone + Cas9 





















































Repressed clone + sgMORC2 





MORC2 ATPase CD CW S5 CC1 CC2 CC3 
544 
1032 1 
795 850 490 603 469 265 869 367 
HUSH-repressed HeLa GFP reporter clone 






































MORC2 knockout HeLa GFP reporter clones 
MORC2 KO #1 MORC2 KO #2 MORC2 KO #3 
c d 
f 
IB: V5 (MORC2) 




MORC2 knockout HeLa cells + 
 V5-MORC2 deletion mutants 
150 
75 
+ wild-type MORC2 















+ ΔATPase-S5 + ΔCW 
+ ΔCD 
GFP reporter 
+ ΔCC1 + ΔCC2 + ΔCC3 
Repressed clone MORC2 knockout MORC2 knockout 























2739 228 490 
4500 
All V5-MORC2 peaks 
V5-MORC2 peaks overlapping TSS 























































  TSS V5-MORC2 








































































































-5000 bp 5000 bp -5000 bp 5000 bp 



























IB: V5 (MORC2) 
b 
V5-MORC2 





Differential Viral Integration (DIVA) 
Wild-type MORC2 knockout 
Euchromatin Heterochromatin 
IB: V5 (MORC2) 
100 
150 
IB: Lamin B1 
75 
MORC2 KO HeLa cells 
+ wild-type MORC2 















+ MORC2 N39A + MORC2 D68A 
GFP reporter 
e 

























































































































DIVA decompacted loci 










0 5 10 15 20 25 30
Zinc finger genes









Loci more accessible to viral integration in 
MORC2 knockout cells, P < 0.05 (n = 278) 
All genomic loci (10 kb intervals)  
Figure 4 
MORC2 









Figure 5 a c 
8 


























log2 read counts wild-type 
Decreased H3K9me3 in 
 MORC2 knockout HeLa cells 
b 
DIVA decompacted loci 
















Wild-type Mean 1SD 2SD 
Averaged H3K9me3 across  
DIVA decompacted loci (n = 278) 
MORC2 KO Mean 1SD 2SD 
H3K9me3 ChIP-seq in HeLa cells 
d 
Genes residing in loci exhibiting decompaction 


























log2 read counts wild-type 
Increased expression in 
MORC2 knockout cells 
Genes residing in DIVA  
decompacted loci 










































DIVA decompacted loci 
(n = 278) 
Genes exhibiting significantly altered expression 


























log2 read counts wild-type 
Decreased expression in 
MORC2 knockout cells 
(272 genes) 
Increased expression in 




































0 2 4 6
Histone cluster genes
Zinc finger genes
DAVID gene function enrichment score 
Genes upregulated in 
MORC2 knockout HeLa cells (n = 190) 
(9 / 190) 
(29 / 190) 
e 
Figure 6 a 
b d 
MORC2 ATPase CD CW S5 CC1 CC2 CC3 
554 
1032 1 







+ wild-type MORC2 
Genetic complementation of 
















+ MORC2 R252W 
Repressed clone 
MORC2 knockout 
+ exogenous MORC2 
+ exogenous MORC2 






IB: V5 (MORC2) 

















































































































































0 4 7 9 12 14
GFP reporter hyper-repression 
by MORC2 R252W in 
MORC2 knockout HeLa cells 
+ wild-type MORC2 



















































All genes hyper-repressed by 
R252W MORC2 P < 0.05 (n=91) 
ZNF genes hyper-repressed by 
R252W MORC2 P < 0.05 (n=31) 
Hyper-repression 
by R252W MORC2 
in SK-N-SH cells 
e GFP reporter hyper-repression 
by MORC2 R252W in 

































































Figure 6 a 
b d 
MORC2 ATPase CD CW S5 CC1 CC2 CC3 
554 
1032 1 







+ wild-type MORC2 
Genetic complementation of 
















+ MORC2 R252W 
Repressed clone 
MORC2 knockout 
+ exogenous MORC2 
+ exogenous MORC2 






IB: V5 (MORC2) 




























































































































GFP reporter hyper-repression 
by MORC2 R252W in 
MORC2 knockout HeLa cells 
+ wild-type MORC2 



















































All genes hyper-repressed by 
R252W MORC2 P < 0.05 (n=91) 
ZNF genes hyper-repressed by 
R252W MORC2 P < 0.05 (n=31) 
Hyper-repression 
by R252W MORC2 
in SK-N-SH cells 
e GFP reporter hyper-repression 
by MORC2 R252W in 














































































0 4 7 9 12 14 
0
0.2
0.4
0.6
0.8
1
1.2
